|Post-Approval Studies are an Essential Phase of Drug Development with Important Implications for Life Science CompaniesPublish the , in News, Publications, White Papers|
The intrinsic differences between clinical trials and real-life utilization of drugs create treatment and safety gaps that can undermine return on investment for drug manufacturers. Safety issues and reduced efficacy observed in real-life can limit the success of marketed drugs. In addition, these gaps also increase costs to society while maintaining a high burden of illness. It is essential for all stakeholders to continue to generate more evidence to achieve optimal effectiveness and safety.